6Turktas H, Unsal M, Tulek N, et al. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazidand and pyrazinamide) or viral hepatitis.Tuber Lung Dis, 1994, 75: 58-60.
7Jasmer RM, Daley CL. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe? Am J Respir Crit Care Med,2003, 167: 809-810.
8Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf, 2001, 24: 483-490.
9Kunimoto D, Warman A, Beckon A, et al. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity. Clin Infect Dis, 2003, 36: 158-161.
10Castro KG, Jereb JA, Koppaka VR, et al. Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection. Chest, 2003, 123: 967.
